Table 2 Publications investigating EVs from cardiomyocytes.

From: Evaluation of the cardioprotective potential of extracellular vesicles – a systematic review and meta-analysis

Ref.

PM

Size

Injury model

Main effector

EV marker

Garcia et al.21

UC, sucrose cushion, precipitation

≈50–100 nm*

NSI

NSI

CD63, CD9, CD81

Borosch et al.33

Size-exclusion chromatography, UC

≈150 nm

NSI

NSI

Alix, HSP70, CD63, Flot-1, CD81

Ribeiro-Rodrigues et al.30

UC

111–137 nm

MI, H2O2

miR-222, miR-143

Alix, HSP70, CD63, Flot-1, TSG-101, CD81, GAPDH

Zhang et al.43

Precipitation

NSI

NSI

(HSP20)

NSI

X. Wang et al.24

UC

54.9–55.2 nm

Streptozotocin induced diabetes

HSP20

CD63, CD81, HSP70

  1. EV-purification method (PM), particle size, investigated injury model, main effector mediating protection are stated and EV marker. UC = ultracentrifugation; HSP = heat shock protein; MI = myocardial infarction; NSI = not specifically indicated; Ref. = reference; TSG = tumour susceptibility gene; Flot = flotillin; GAPDH: glyceraldehyde 3-phosphate dehydrogenase; *self-assessed (assumption made from EM images).
Back to article page